Massimo Breccia

Pubblicazioni

Titolo Pubblicato in Anno
Early Palliative Home Care versus Hospital Care for Patients with Hematologic Malignancies: A Cost-Effectiveness Study JOURNAL OF PALLIATIVE MEDICINE 2020
5. Balanced and Unbalanced Chromosomal Translocatios in Myelodysplastic Syndromes: Clinical and Prognostic Signficance. LEUKEMIA & LYMPHOMA 2020
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy LEUKEMIA 2020
Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached ECLINICALMEDICINE 2020
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index LEUKEMIA 2020
First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an ``operational cure{''} THE LANCET. HAEMATOLOGY 2020
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial LEUKEMIA 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data HEMATOLOGICAL ONCOLOGY 2020
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA) CANCER MEDICINE 2020
Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors LEUKEMIA 2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors ANNALS OF HEMATOLOGY 2020
Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism HAEMATOLOGICA 2020
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia FRONTIERS IN ONCOLOGY 2020
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. ACampus CMLstudy BLOOD CANCER JOURNAL 2020
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the ``Ph1-negative Myeloproliferative Neoplasms Latium Group{''} EUROPEAN JOURNAL OF HAEMATOLOGY 2020
Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning BRITISH JOURNAL OF HAEMATOLOGY 2020
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey LEUKEMIA 2020
How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey LEUKEMIA 2020
Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previousTKIs AMERICAN JOURNAL OF HEMATOLOGY 2020
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib HEMATOLOGICAL ONCOLOGY 2020

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma